The Immortality Update: Deep Research on the Most Important Discoveries and News in Longevity Sciences from the Past 7 Days

Introduction: The Healthspan Horizon

Core Theme: The Primacy of Function

The field of longevity science is undergoing a profound and necessary maturation. For decades, the popular and scientific imagination was captured by the pursuit of extending lifespan—the simple chronological measure of how long a person lives. However, a growing consensus among researchers, clinicians, and ethicists recognizes the inherent emptiness of adding years to life without also adding life to those years. This past week's developments in the field powerfully underscore this paradigm shift, moving the focus from the crude metric of lifespan to the far more meaningful goal of extending **healthspan**: the period of life spent in good health, free from chronic disease and significant physical or mental disability.[1]

This philosophy, championed by the geroscience community, is built on the concept of "compressing morbidity".[4] The objective is not to create a population of frail, dependent nonagenarians and centenarians, but to shorten the period of decline at the end of life, allowing individuals to maintain a high degree of physiological function, cognitive acuity, and independence for as long as possible.[4] The research and clinical announcements from the last seven days are exemplary of this mission in practice. They are not aimed at merely postponing death but at actively targeting the fundamental biological mechanisms of aging—such as impaired proteostasis, mitochondrial dysfunction, and the decline of endogenous repair systems—that underlie the loss of function.[4] This strategic focus on maintaining vitality represents

the most promising path toward achieving not just a longer life, but a better one.

Executive Summary of Key Developments

The past week has been marked by a powerful convergence of distinct but complementary technological and therapeutic frontiers, each contributing to the goal of enhancing functional life. This report will provide an exhaustive analysis of three primary pillars of progress that have emerged:

1. **Precision Cellular Engineering for Neurodegeneration:** In a landmark proof-of-concept study, the core technology of Chimeric Antigen Receptor (CAR) immune cells, a revolutionary tool in modern oncology, has been successfully repurposed to address the specific pathological hallmarks of Alzheimer's disease. This represents a potential paradigm shift in the treatment of age-related neurodegenerative decline, moving from broad-acting drugs to highly targeted, living cellular therapies.[9]
2. **Clinical-Stage Organ Regeneration:** A novel, first-in-class small-molecule inhibitor has officially entered human clinical trials. Its express purpose is to stimulate the liver's innate regenerative capacity, offering a direct therapeutic intervention designed to restore organ function and dramatically improve surgical outcomes for critically ill patients. This marks a critical transition of regenerative science from the laboratory to the clinic.[12]
3. **Acceleration via Technology:** The landscape of longevity research is being reshaped by powerful new enabling technologies. The launch of a sophisticated AI-driven drug discovery platform and the validation of a next-generation epigenetic biomarker highlight how technology is becoming the central engine for both identifying novel healthspan interventions and, crucially, measuring their efficacy with unprecedented precision.[15]

A critical underlying trend connecting these disparate announcements is the emergence of interoperable therapeutic and diagnostic platforms. The field is moving away from siloed research programs focused on single genes or pathways and into a new era of synergistic, cross-disciplinary problem-solving. We are witnessing the fusion of validated components from one field being integrated into another to create novel solutions with reduced risk and accelerated timelines. For instance, the Buck Institute's Alzheimer's research does not invent a new targeting mechanism from scratch; it effectively takes the validated "software" of well-characterized antibody

fragments from immunology and "installs" it onto the "hardware" of a cellular delivery platform (CAR immune cells) to create a new therapeutic for neuroscience.[9] Similarly, HepaRegeniX is applying a classic small-molecule drug development approach to unlock a fundamental biological process—organ regeneration—that has historically been the domain of more complex cell therapies or biologics.[12] At the same time, Fauna Bio's AI platform serves as a translation engine, converting biological insights from the domain of animal extremophiles into druggable targets for human metabolic disease.[15] Finally, the new IC Clock is a diagnostic platform that integrates molecular data (DNA methylation) with high-level clinical data (WHO functional assessments) to create a single, validated metric of healthspan.[16] These are not isolated events. They collectively signal a strategic shift in the R&D paradigm for longevity science. The key to rapid progress is no longer just discovering a single new biological target, but creating and combining modular, interoperable platforms. This "platform-of-platforms" approach allows for faster, de-risked, and more innovative therapeutic and diagnostic development, representing a fundamental and highly significant change in how the battle against age-related decline will be fought.

Key Findings: Novel Interventions Targeting Functional Decline

Cellular Engineering for Neuro-Rejuvenation: The CAR-T Approach to Alzheimer's Disease

The Breakthrough

In a development that could reshape the therapeutic landscape for neurodegenerative diseases, a proof-of-concept study from the Buck Institute for Research on Aging, published in the *Journal of Translational Medicine*, has demonstrated the successful engineering of immune cells with Chimeric Antigen Receptors (CARs) that can specifically recognize and respond to the key pathological proteins implicated in Alzheimer's disease (AD).[9] This work takes one of the most

powerful tools in modern medicine—CAR-T cell therapy, which has revolutionized the treatment of certain blood cancers—and repurposes it for a completely different and notoriously difficult therapeutic area. The study provides the first evidence that this highly adaptable cellular therapy platform can be programmed to target the complex pathologies of the aging brain.

Mechanism of Action - Precision Targeting

The elegance of the Buck Institute's approach lies in its precision. Previous therapeutic attempts in Alzheimer's, particularly anti-amyloid antibody drugs, have often acted as a "sledgehammer," targeting amyloid plaques broadly and sometimes leading to significant side effects like brain swelling and bleeds (amyloid-related imaging abnormalities, or ARIA).[9] The engineered CARs described in this new research are designed to be a "targeted scalpel".[10]

Researchers constructed a suite of CARs using the single-chain fragment variable (scFv) portions of well-known and clinically validated Alzheimer's antibodies. These included CARs based on Aducanumab and Lecanemab, which target aggregated forms of amyloid-beta (Aβ), and, crucially, CARs based on Donanemab and Remternetug, which specifically target a highly toxic, truncated, and aggregation-prone form of Aβ known as pyroglutamated Aβ (Aβp3-42).[11] They also successfully developed a CAR targeting tau fibrils, the other major pathological hallmark of AD.[11] In their

in vitro experiments using a mouse T-cell hybridoma line, the researchers showed that these CAR-expressing cells could be activated specifically by their cognate targets. For example, the Adu-CAR and Rem-CAR responded strongly to their respective Aβ aggregate targets, while the tau-targeting CAR responded selectively to tau fibrils.[10] This ability to discriminate between different pathological protein species and even different conformations of the same protein is a critical advance. It opens the door to therapies that can be tailored to a patient's specific pathology and selectively eliminate the most toxic protein forms while leaving benign or functional forms untouched, potentially leading to a much more favorable safety profile.

Paradigm Shift - "Heal, Not Kill"

Perhaps the most significant conceptual advance in this research is the deliberate shift away from the established oncological paradigm of CAR-T therapy. In cancer treatment, CAR-T cells are engineered to be cytotoxic; their primary function is to identify and kill tumor cells.[21] Applying such a destructive mechanism to the brain, where preserving neuronal function is paramount, would be counterproductive and dangerous.

The Buck Institute's vision for this technology is fundamentally different. The researchers explicitly state that their cells are designed to "heal, not kill".[9] The ultimate goal is not simply to use the CARs as a targeting system for a cellular weapon, but to turn the engineered immune cells into autonomous, mobile biological factories.[9] In this model, the CAR serves as a guidance system, directing the cell to a site of pathology (e.g., an amyloid plaque or a neurofibrillary tangle). Once there, the cell would be programmed to release a therapeutic payload—such as anti-inflammatory cytokines, neurotrophic factors that support neuron survival, or enzymes that help dismantle the protein aggregates—directly into the local microenvironment.[23] This approach aims to resolve the pathology and reduce neuroinflammation while actively supporting the health of surrounding neurons. This represents a profound shift from a strategy of targeted destruction to one of targeted repair and rejuvenation.

This research demonstrates a highly sophisticated form of R&D arbitrage, a strategy that significantly de-risks the development of this novel therapeutic platform. The single greatest challenge and source of failure in developing any targeted therapy is ensuring that the targeting molecule—the antibody, the small molecule, the aptamer—binds with high affinity and specificity to its pathological target *in vivo*. Pharmaceutical companies like Biogen, Eli Lilly, and Eisai have invested billions of dollars and decades of research into preclinical studies and massive Phase III clinical trials to develop and validate the antigen-binding domains of antibodies like aducanumab, lecanemab, and donanemab.[24] They have already done the hard work of proving that these specific protein sequences can effectively find and bind to Aβ plaques within the complex environment of the human brain.

The Buck Institute team is not attempting to reinvent this high-risk component. Instead, they are strategically taking these proven "targeting heads" and grafting them onto a new therapeutic "chassis"—the CAR-immune cell platform.[9] This modular, "plug-and-play" approach allows them to bypass the most expensive and failure-prone stage of discovery and focus on optimizing the cellular delivery vehicle and its therapeutic function. This is more than simple repurposing; it points toward a

new R&D model where validated targeting domains could become licensable assets. A company could develop a single, highly effective CAR-Treg or CAR-macrophage platform and then rapidly generate an entire pipeline of therapeutics by licensing different validated scFv "apps" to install on their cellular "operating system." This model dramatically accelerates development timelines, lowers early-stage capital requirements, and reduces scientific risk, making it an exceptionally compelling strategy from a biopharma investment and analysis perspective.

Unlocking Organ Regeneration: The HRX-215 Clinical Trial for Liver Health

The Milestone

In a major development for the field of regenerative medicine, the German biotechnology company HepaRegeniX announced this past week that it has dosed the first patient in a randomized, double-blinded, placebo-controlled Phase Ib/IIa clinical trial (NCT06638502) for its lead candidate, HRX-215.[12] This announcement is highly significant as it marks the transition of a promising organ regeneration therapy from pre-clinical research into human efficacy testing, a critical step toward addressing a major unmet medical need in patients with advanced liver disease. The trial, which is being conducted in the United States, represents one of the first major clinical tests of a small-molecule drug designed specifically to enhance the body's own regenerative capabilities to restore organ function.

Mechanism of Action - Releasing the Brakes on Regeneration

HRX-215 is a first-in-class, orally available small-molecule inhibitor of Mitogen-Activated Protein Kinase Kinase 4 (MKK4).[12] MKK4 is a crucial signaling protein that, under conditions of cellular stress, acts as a key regulator and a natural "brake" on the proliferation of hepatocytes, the primary functional cells of the liver.[27] The therapeutic hypothesis is that by selectively inhibiting MKK4, the drug can release this brake, thereby unleashing the liver's powerful and innate capacity to regenerate,

even in the context of underlying disease or damage.[12]

This approach is supported by compelling preclinical data. In studies published in the journal *Cell*, MKK4 inhibition was shown to dramatically boost liver regeneration and prevent post-hepatectomy liver failure (PHLF) in both mouse and pig models.[12] In a particularly striking experiment, the administration of an MKK4 inhibitor allowed pigs to survive a normally lethal 85% liver resection, a feat that was impossible in control animals.[29] The preclinical work also revealed that the compound has beneficial anti-steatotic (fat-reducing) and anti-fibrotic (scar-reducing) effects, suggesting its potential utility beyond acute settings.[28] Following these promising results, a Phase I trial in healthy human volunteers established a favorable safety and pharmacokinetic profile for HRX-215, paving the way for the current clinical trial in patients.[30]

Direct Functional Impact

The design of the Phase Ib/IIa trial highlights the therapy's focus on a direct, tangible functional outcome. The study is enrolling 85 patients who have liver metastases originating from colorectal cancer and are scheduled to undergo partial liver resection.[12] For many of these patients, surgery offers the only hope for a cure, but it is often not an option. A major limiting factor is the size and health of the "future liver remnant" (FLR)—the portion of the liver that will remain after the surgery. If the FLR is too small or its function is compromised by underlying conditions like steatosis or fibrosis, the patient is at extremely high risk of developing fatal post-operative liver failure.[26]

The primary functional goal of HRX-215 in this trial is to stimulate the rapid regeneration of the hepatocytes in the FLR, effectively growing the remnant liver to a safe size and improving its function prior to or immediately after surgery. By doing so, the therapy aims to increase the safety and feasibility of liver resection, making this potentially curative surgery available to a larger population of patients who are currently deemed inoperable.[12] The trial is structured into three cohorts to evaluate the drug's effect in patients undergoing both minor (

<30%) and major (50–72%) resections, with a placebo arm included for the major resection group to rigorously assess efficacy.[12] An initial data readout is anticipated in the second half of 2025.[13]

The initiation of the HRX-215 trial represents a pivotal move away from the traditional medical model of simply managing the symptoms of organ decline and toward a new, more ambitious paradigm of actively restoring organ function. This approach directly targets a core hallmark of aging: the progressive decline of the body's endogenous repair and regenerative capabilities. Standard medical care for end-stage liver disease is largely palliative, aimed at managing complications like ascites and encephalopathy, or focused on removing the source of the injury, such as prescribing antiviral medications for hepatitis or enforcing abstinence for alcohol-related liver disease.[32] The only truly curative option is a liver transplant, a procedure that is severely limited by a chronic shortage of donor organs, high costs, and the need for lifelong immunosuppression.[34]

HRX-215 is not a supportive care drug or an antiviral. It is a pro-regenerative agent designed to awaken and amplify the body's own powerful repair mechanisms.[12] The clinical endpoint of the current trial is explicitly and functionally oriented: to enable a life-saving surgery that was previously too dangerous for the patient to undergo.[12] This is a direct, measurable enhancement of the patient's fundamental physiological capacity. If this approach proves successful, it will do more than just add another drug to the hepatologist's toolkit. It will create an entirely new therapeutic class of what could be termed "pre-surgical regenerative conditioning" agents. This would not only be a breakthrough for treating liver disease but could also become an enabling technology with the potential to transform the fields of surgical oncology, trauma care, and transplantation medicine. By making more patients robust enough to withstand major curative procedures, such therapies could fundamentally change clinical practice and improve survival across a wide range of devastating conditions.

Early-Stage Research vs. Clinical Trials: Bridging the Translational Gap

A Comparative Analysis of the Week's Therapeutic Pipeline

The longevity science developments from the past seven days provide a perfect, real-world snapshot of the biopharmaceutical research and development pipeline,

illustrating the distinct stages from high-potential basic science to mid-stage clinical validation. The contrast between the two key therapeutic findings—the CAR-immune cell approach for Alzheimer's and the HRX-215 trial for liver regeneration—is particularly instructive.

Pre-clinical Promise (CAR-T for AD)

The Buck Institute's work on engineering CAR-immune cells for Alzheimer's disease is a foundational, *in vitro* proof-of-concept study.[9] While scientifically elegant and holding immense long-term promise, it resides at the very earliest stage of the translational pathway. The research successfully demonstrates that the principle works in a laboratory setting using mouse cells. However, the journey from this initial discovery to a viable human therapy is exceptionally long and fraught with significant scientific, technical, and regulatory hurdles.

Key challenges that must be overcome include:

- ***In Vivo* Efficacy:** The therapy must be proven to work in a living organism, specifically in an animal model that recapitulates the key features of Alzheimer's disease. Researchers will need to show that the engineered cells can effectively cross the formidable blood-brain barrier, traffic to the sites of pathology, and exert their intended therapeutic effect.[35]
- **Safety and Toxicity:** The central nervous system is an immunologically sensitive environment. The introduction of engineered, self-renewing immune cells carries substantial risks, including the potential for uncontrolled inflammation, neurotoxicity, cytokine release syndrome (CRS), and off-target effects that could damage healthy brain tissue.[21] Establishing a safe dose and administration protocol will be a monumental task.
- **Manufacturing and Scalability:** Autologous CAR-T therapies, which are made from a patient's own cells, involve a complex and expensive manufacturing process that takes weeks.[21] Developing a process that is scalable, reliable, and affordable for a disease with the prevalence of Alzheimer's will be a major logistical and economic challenge.

Human Application (HRX-215)

In stark contrast, HepaRegeniX's HRX-215 has already navigated the perilous "valley of death" that separates preclinical research from human trials. Having successfully completed Phase I studies that established its safety and pharmacokinetic profile in healthy volunteers, the drug is now being tested for efficacy in a well-defined patient population with a clear unmet medical need.[12]

The primary risks for the HRX-215 program are no longer centered on fundamental biological plausibility—the preclinical data has already established that—but on its performance in a real-world clinical setting. The key questions now are:

- **Clinical Efficacy:** Will the drug's pro-regenerative effect be potent enough in sick patients with compromised liver function to achieve the primary endpoint of enabling surgery?
- **Safety in Patients:** While safe in healthy volunteers, will the drug have an acceptable side-effect profile in a more vulnerable patient population undergoing major surgery and dealing with metastatic cancer?
- **Dose Optimization:** What is the optimal dose and duration of treatment to maximize regenerative effects while minimizing potential risks?

The juxtaposition of these two groundbreaking developments offers a clear and practical illustration of the different stages of the biopharma R&D lifecycle. For a life sciences analyst, this serves as an invaluable case study in how to evaluate and value therapeutic assets at different points in their development trajectory. The CAR-T for Alzheimer's project is a platform technology. Its potential applications are vast, but its future is highly uncertain. Its current valuation would be based on factors such as the strength of its intellectual property, the reputation of the research team, and the sheer size of the potential Alzheimer's market, all of which would be discounted heavily to account for the immense technical, clinical, and regulatory risks that lie ahead.

The HRX-215 asset, on the other hand, is a specific drug candidate with a defined clinical path and a clear initial indication. Its valuation is far more concrete. It would be based on the strength of its existing Phase I data, the design and statistical power of the current Phase Ib/IIa trial, the size of its initial addressable market (patients requiring liver resection due to colorectal cancer metastases), and a calculated probability of clinical success and regulatory approval. Analyzing these two stories together provides more insight than analyzing them in isolation. It demonstrates the flow of capital and risk within the longevity industry. Early-stage, high-risk capital from sources like government grants and specialized venture funds is required to

support foundational work like that being done at the Buck Institute. Later-stage, more risk-averse capital from larger venture rounds, public markets, and pharmaceutical partnerships is needed to fund expensive clinical trials like the one being run by HepaRegeniX. In essence, this week's news provides a perfect microcosm of the entire bio-investment ecosystem, from blue-sky discovery to late-stage clinical development.

Table 1: Weekly Longevity Intervention Pipeline

The following table provides a structured, at-a-glance summary of the key therapeutic interventions detailed in this week's report, allowing for rapid comparison of their mechanisms, development stages, and functional goals.

Intervention Name	Lead Institution/Company	Mechanism of Action	Target Indication	Development Stage	Primary Functional Goal
CAR-Immune Cells	Buck Institute	Engineered immune cells with CARs targeting specific toxic Aβ and tau species.	Alzheimer's Disease	Pre-clinical (in vitro, mouse cells)	Clear pathological proteins, reduce neuroinflammation, and "heal" the brain environment to preserve neuronal function.
HRX-215	HepaRegeniX GmbH	Oral small-molecule inhibitor of MKK4 kinase.	Post-Hepatectomy Liver Failure (in patients with colorectal cancer metastases)	Clinical (Phase Ib/IIa)	Stimulate liver regeneration to increase the future liver remnant (FLR), enabling curative surgery for previously

					inoperable patients.

Technological Tools: Accelerating the Discovery and Measurement of Healthspan

AI-Driven Discovery: The Fauna Brain Platform

The Launch

In a significant development for the application of artificial intelligence in biotechnology, Fauna Bio, a firm specializing in comparative genomics, has officially launched Fauna Brain™. This multi-agent AI platform is engineered to dramatically accelerate the discovery of novel drug targets and streamline the early stages of research and development.[15] The platform represents a major evolution of the company's underlying Convergence™ discovery engine and is already being deployed in both internal programs and external pharmaceutical partnerships.

Unique Methodology - Learning from Nature's Survivors

The core innovation that distinguishes Fauna Brain from other AI-driven drug discovery platforms is its unique data source and underlying philosophy. Instead of relying solely on human genomic data, which is often biased towards disease states, Fauna Brain leverages the company's vast and proprietary Convergence™ dataset. This dataset includes a rich collection of genomic, transcriptomic, and proteomic information from 292 different animal species, many of which are known for their

extraordinary physiological resilience and unique adaptations.[15]

These "extremophiles" include species like the 13-lined ground squirrel, which can endure long periods of hibernation without significant muscle atrophy or organ damage; the spiny mouse, which can regenerate skin and other tissues without scarring; and elephant seals, which are resistant to metabolic disorders despite massive fluctuations in body fat.[41] The fundamental task of the AI is to delve into this evolutionary treasure trove to identify the conserved genetic and molecular mechanisms that confer these remarkable protective traits. It then maps these protective biological signatures to human disease pathways to uncover novel, druggable targets that would likely be missed by human-only studies.[18] The platform's AI engines—named Orca, Centaur, and Pegasus—autonomously execute complex research workflows, including identifying and ranking targets, synthesizing scientific evidence, and generating comprehensive concept sheets complete with mechanistic rationale and risk-benefit analyses.[18]

Demonstrated Potential

The platform's capabilities are not merely theoretical. Fauna Bio reports that Fauna Brain can evaluate and score a potential drug target in as little as 2.5 minutes at an average cost of approximately $0.01, and it can screen thousands of candidates in parallel.[38] This represents a massive increase in speed and a dramatic reduction in cost compared to traditional R&D methods.

More importantly, the platform has already demonstrated tangible translational potential. The company revealed that two drug targets prioritized by Fauna Brain have already progressed into a funded research collaboration with pharmaceutical giant Eli Lilly, a multi-year agreement focused on discovering new treatments for obesity that could be worth up to $494 million.[42] This provides powerful external validation of the platform's ability to generate valuable and actionable therapeutic hypotheses. Fauna Bio's internal pipeline, guided by the platform, includes programs in heart failure (with a lead candidate, Faun1083, derived from hibernation-adapted genes), neuroprotection, and retinal diseases, with emerging applications in space health and radiation resistance.[18]

The launch of the Fauna Brain platform represents a fundamental philosophical shift in the source of biological inspiration for drug discovery. For decades, the dominant

model has been pathology-centric. Research typically begins with data from sick humans; scientists analyze the genetics of a disease to identify a malfunctioning pathway or protein that can be inhibited with a drug. Fauna Bio's approach inverts this model. It starts with data from exceptionally healthy or uniquely resilient animals to find protective biological mechanisms that can be *activated* or mimicked in humans.[15] This is a salutogenesis-centric, or health-originating, model. The artificial intelligence component is the critical enabling tool that can bridge the vast evolutionary gap between species. The AI can find the conserved "protective software" in the genome of a hibernating squirrel and identify its human homolog, which can then be targeted with a drug to treat a condition like heart failure with preserved ejection fraction (HFpEF), as is the case with their candidate Faun1083.[18]

This approach fundamentally alters the strategic landscape of data acquisition for the pharmaceutical and biotechnology industries. It strongly suggests that the next wave of breakthrough therapies may not be found by simply sequencing another million human genomes from established biobanks. Instead, the most valuable and novel insights may come from sequencing the diverse and extreme biology of the planet. This has profound implications for R&D strategy, future investment in biodiversity and genomics, and the very definition of what constitutes a valuable biological dataset.

Biomarkers of Function: The "Intrinsic Capacity" (IC) Epigenetic Clock

The Development

In a major advance for the measurement of biological aging, an international consortium of researchers, including scientists from the prestigious Buck Institute for Research on Aging in the U.S. and the IHU HealthAge in France, has developed and validated a new blood-based epigenetic clock. Dubbed the "IC Clock," this new biomarker was detailed in a study published in the high-impact journal *Nature Aging*.[16] Unlike its predecessors, the IC Clock is specifically designed to measure functional healthspan rather than just chronological age.

Validation and Superiority

The IC Clock was constructed using DNA methylation data from the INSPIRE-T cohort, which includes over 1,000 individuals ranging in age from 20 to 102.[16] Its key innovation is that it was not trained to predict chronological age, but was instead trained to predict "Intrinsic Capacity" (IC). IC is a comprehensive concept of healthy aging developed by the World Health Organization (WHO), which defines it as the composite of an individual's physical and mental capacities across six key functional domains: locomotion (mobility), cognition, psychological well-being, vitality (energy and metabolism), vision, and hearing.[16]

In rigorous validation studies using data from the long-running Framingham Heart Study, the IC Clock demonstrated remarkable predictive power. It was found to outperform all first-generation (e.g., Horvath, Hannum) and second-generation (e.g., PhenoAge, GrimAge) epigenetic clocks in predicting all-cause mortality.[19] An individual's score on the IC clock was a more powerful predictor of their risk of death than any previous epigenetic aging measure.

Crucially, the clock's score correlated strongly with real-world functional outcomes. Individuals with higher IC Clock scores (indicating better intrinsic capacity) also had better lung function, faster walking speeds, greater bone mineral density, and were more likely to report being in good health.[46] The research also found strong associations between high IC scores and better immune system performance, lower levels of chronic inflammation, and healthier lifestyle choices, such as lower sugar intake.[16] This demonstrates that the IC Clock is not just an abstract statistical model but a robust measure that taps into the core biological processes that determine how well a person is aging.

Clinical and Research Utility

As a non-invasive tool that uses DNA methylation patterns from a simple blood or saliva sample, the IC Clock offers a scalable and cost-effective way to assess functional decline in both clinical and research settings.[16] Its potential applications are vast. In clinical practice, it could be used to identify at-risk individuals early and guide personalized, preventative interventions. In research, it can serve as a powerful

biomarker to measure the efficacy of healthspan-extending therapies.

Demonstrating its immediate relevance and acceptance by the scientific community, the IC Clock has already been selected for use in the $101 million XPRIZE Healthspan competition. It will be one ofthe key tools used by the competing teams, including the team from the Buck Institute and the University of Toulouse, to track and analyze the responses of participants to their proposed longevity interventions.[16]

The development of the IC Clock may represent more than just an incremental improvement in biomarker technology; it could be the critical tool that solves one of the most significant regulatory hurdles in the entire field of longevity science: the lack of a validated surrogate endpoint for "aging." Currently, the U.S. Food and Drug Administration (FDA) approves drugs to treat specific, defined diseases. "Aging" itself is not classified as a disease, which makes it virtually impossible for a company to get a drug approved for a general "anti-aging" or "healthspan-extending" indication.[16] This has been a major bottleneck for the development of gerotherapeutics.

To overcome this, the field has desperately needed a validated biomarker that reliably tracks the progression of age-related functional decline, a state which *can* be defined as a pathological condition. Previous epigenetic clocks fell short because they were primarily trained on chronological age or all-cause mortality, which are not direct measures of function or disease. The IC Clock is the first biomarker to be specifically trained on and validated against a comprehensive, clinically relevant, and internationally recognized definition of functional health—the WHO's concept of Intrinsic Capacity.[16] The WHO has already taken the crucial step of recognizing a decline in IC as a diagnosable condition in its International Classification of Diseases, 11th Revision (ICD-11).[16]

This creates a potential regulatory pathway that did not exist before. A pharmaceutical company could now design a clinical trial with the primary endpoint of improving a patient's IC Clock score. If the trial successfully demonstrates that an intervention significantly and safely improves this score, regulators like the FDA might be able to accept that as evidence of treating the recognized "condition" of age-related functional decline. This would create a clear and viable regulatory path for healthspan-focused drugs, a development that could unlock billions of dollars in research and development investment and truly catalyze the entire field of geroscience.

The Quantified Self: Advances in Wearable Health Monitoring

The Trend

The role of wearable technology in healthcare continues to evolve at a rapid pace, moving beyond simple fitness tracking towards becoming an integral part of personalized and proactive medical care. Expert discussions from the Mayo Clinic, highlighted in their "Tomorrow's Cure" series this week, emphasize this ongoing transformation. The consensus is that data from wearable devices is no longer a novelty but a crucial tool for personalizing care, managing chronic conditions, and predicting changes in a patient's health trajectory long before they become clinically apparent.[47] These devices empower patients to take a more active role in their own health and provide clinicians with a continuous stream of longitudinal data that is far richer than the snapshots provided by occasional clinic visits.[47]

New Hardware

Exemplifying this trend towards more sophisticated and medically relevant wearables, researchers from the University of Oxford and University College London announced a groundbreaking new device in the journal *Nano-Micro Letters* this week: an AI-enabled piezoelectric wearable sensor for joint health monitoring.[48] This is not a general-purpose fitness tracker. It is a specialized, low-cost device designed for a specific functional purpose. It uses a unique composite material of boron nitride nanotubes in a polymer matrix and an inverse-designed structure that allows it to conform perfectly to the biomechanics of the knee joint.

The key innovation is the integration of a lightweight, on-device artificial neural network. This AI algorithm can process the complex piezoelectric signals generated during movement in real time to provide an accurate, continuous assessment of critical biomechanical parameters, including joint torque, angle, and load.[48] This allows for the precise tracking of a key functional domain—mobility—and can be used for a variety of healthspan-related applications, such as guiding rehabilitation after injury, monitoring the progression of musculoskeletal conditions like osteoarthritis, and

providing real-time risk assessment for injury prevention in the elderly and in athletes.[48]

The evolution of wearable technology is clearly moving beyond the passive collection of simple biometric data towards the integration of specialized sensors with on-device AI to provide real-time, actionable assessments of specific functional domains. First-generation wearables were essentially digital pedometers and data loggers.[49] The second generation, represented by devices like the Apple Watch and WHOOP strap, incorporated more sophisticated sensors and cloud-based algorithms to track more complex metrics like sleep stages, heart rate variability (HRV), and VO_2 max, providing valuable retrospective insights into a user's health.[49]

The new joint-monitoring device announced this week represents the emerging third generation of this technology. It features a purpose-built sensor designed to measure a specific physiological function (in this case, joint mechanics) and combines it with an on-device AI that provides real-time, predictive analysis (such as injury risk).[48] This points to a future where individuals will not rely on a single, all-purpose device, but will instead use a suite of specialized wearables. One might wear a continuous glucose monitor (CGM) for metabolic health, a device with a validated ECG for cardiovascular health, and a sensor like this one for musculoskeletal health.

The data streams from these various specialized sensors would then feed into a central AI hub, creating a comprehensive "digital twin" of the individual. This system would provide a continuous, multi-domain, real-time assessment of an individual's functional healthspan, moving beyond simple tracking to enable truly personalized, predictive, and proactive interventions designed to maintain function and extend the quality of life.

Ethical and Practical Considerations: Navigating the New Frontier

The Ethics of Engineered Cells for Neurodegeneration (CAR-T for AD)

Safety and Risk Profile

The proposal to adapt Chimeric Antigen Receptor (CAR) technology for Alzheimer's disease, while scientifically exciting, carries a formidable set of ethical and safety challenges. Even though the Buck Institute's approach is designed to be restorative rather than cytotoxic, the fundamental risks associated with introducing genetically engineered immune cells into the body remain, and they are amplified by the unique sensitivity of the central nervous system. The two most feared side effects of CAR-T therapy in oncology are cytokine release syndrome (CRS), a massive systemic inflammatory response, and immune effector cell-associated neurotoxicity syndrome (ICANS), which can cause a range of neurological symptoms from confusion to seizures and cerebral edema.[21] The potential for these complications to be catastrophic within the enclosed space of the brain is exceptionally high. Furthermore, the long-term consequences of establishing a population of self-renewing, genetically modified immune cells within the brain are entirely unknown.[35] The FDA and other regulatory bodies will undoubtedly require an extremely high bar for safety to be cleared in extensive preclinical testing before any human trials can be considered.[36]

Informed Consent in Vulnerable Populations

The issue of informed consent presents a particularly profound ethical dilemma for this line of research. Alzheimer's disease, by its very nature, progressively erodes the cognitive capacity required for a person to make complex medical decisions.[25] Obtaining truly informed consent from an individual with even mild cognitive impairment for an experimental, potentially high-risk, and irreversible cell therapy is a monumental challenge. How can a patient who is beginning to lose their memory and executive function be expected to fully grasp the intricate risk-benefit profile, the uncertainty of the outcome, and the potential for severe adverse events? This situation places an immense ethical and emotional burden on clinicians and, more often, on family members who must act as surrogate decision-makers, navigating their own hopes and fears while trying to honor the patient's wishes and best interests.[25]

Accessibility and Equity

Beyond the immediate clinical and ethical concerns, the practical issue of accessibility looms large. Existing CAR-T therapies for cancer are among the most expensive treatments in modern medicine, with costs often running into the hundreds of thousands of dollars per patient, not including the associated costs of hospitalization and managing side effects.[50] If a CAR-T therapy for Alzheimer's were to be developed with a similar cost structure, it would be utterly inaccessible to the vast majority of the millions of people affected by the disease worldwide. This raises the deeply troubling specter of a two-tiered system of healthcare, where revolutionary, function-preserving treatments are available only to the wealthy, while the rest of the population is left to face the ravages of neurodegeneration. This would not only be a failure of public health but a profound social injustice.

A critical error in reasoning would be to apply the ethical calculus used to justify high-risk therapies in terminal oncology to a chronic, progressive neurodegenerative disease like Alzheimer's. The two situations are fundamentally different, and a new, more nuanced ethical framework is urgently needed before human trials of a neuro-CAR-T therapy can be responsibly initiated. In the case of a patient with relapsed, refractory leukemia, they are often facing a near-certain and imminent death. In this context, the potential benefit of a cure, even if the probability is low, can be seen to outweigh the very high risk of severe or even fatal side effects from the therapy.[21] The risk-benefit calculation is heavily skewed by the grim alternative.

In early-stage Alzheimer's disease, the situation is entirely different. The patient is not facing imminent death; they may have many years, or even decades, of life remaining, albeit with declining function. The primary therapeutic goal is not the eradication of a disease at all costs, but the preservation of function, quality of life, and personal dignity.[25] Therefore, the risk of the therapy itself causing a more rapid decline, severe disability, or death is far less acceptable. The ethical principle of non-maleficence (do no harm) must take precedence over beneficence (do good).

Furthermore, there is a particularly insidious risk that has been discussed in the bioethics literature concerning disease-modifying but non-restorative therapies for dementia: the "locked-in" problem.[53] It is conceivable that a therapy could be developed that successfully halts the progression of the underlying pathology—for example, it stops the formation of new amyloid plaques—but fails to restore the cognitive function that has already been lost. Such a "successful" treatment could have the horrific outcome of permanently "locking" a patient in a state of severe

dementia, extending their period of suffering and creating an unimaginable and unsustainable long-term burden on caregivers, families, and the healthcare system. Any ethical framework for neuro-CAR-T must grapple with this possibility and define what constitutes a truly meaningful and beneficial therapeutic outcome when a person's identity and cognitive self are at stake.

The Ethics of AI-Powered Genomics (Fauna Brain)

Data Privacy and Security

The rise of powerful AI platforms like Fauna Brain, which are trained on vast and sensitive genomic datasets, brings with it significant ethical challenges related to data privacy and security. Genomic data is uniquely personal; it contains information not only about an individual's health and ancestry but also about their blood relatives.[55] The risk of data breaches, unauthorized use by third parties, and the re-identification of "anonymized" individuals is substantial and the consequences can be permanent.[57] As these datasets grow and are linked with other forms of data, the ability to protect individual privacy becomes increasingly difficult, demanding the development and implementation of robust security measures like federated learning, homomorphic encryption, and stringent access controls.[56]

Algorithmic Bias and Health Disparities

A well-documented and persistent problem in both artificial intelligence and genomics is the issue of bias. AI models are only as good as the data they are trained on.[60] If the genomic data used to train a platform like Fauna Brain is not fully representative of global human diversity—if it is skewed towards individuals of European ancestry, for example—then the drug targets and therapies it identifies may be less effective, or potentially even harmful, for underrepresented populations.[61] This is not a theoretical concern; it is a known issue in drug development that can lead to the exacerbation of existing health inequities.[63] Ensuring the diversity of training datasets is therefore not

just a technical requirement for building better models, but an ethical imperative for promoting health equity. This bias can also exist in the comparative genomics data itself, where certain animal clades may be over-represented, leading to a skewed understanding of evolutionary biology.[64]

Transparency and Accountability

The "black box" problem is another major ethical hurdle for AI in drug discovery. The decision-making processes of highly complex neural networks can be opaque and difficult for humans to interpret.[61] This lack of transparency poses significant challenges for regulatory oversight, independent scientific validation, and building trust with patients and clinicians.[61] If a drug candidate is proposed by an AI, but researchers cannot fully articulate the biological rationale behind the choice, how can a regulatory body like the FDA confidently assess its safety and efficacy? How can a patient provide informed consent for a trial of a drug whose mechanism was derived by an inscrutable algorithm? Establishing frameworks for accountability and demanding a degree of "explainability" from these AI systems will be critical for their responsible adoption.

The use of comparative genomics from hundreds of non-human species, as pioneered by Fauna Bio, introduces a novel and largely unaddressed set of ethical questions that fall outside the scope of traditional, human-centric bioethics. Current ethical guidelines and data privacy regulations, such as the Health Insurance Portability and Accountability Act (HIPAA) in the U.S. and the General Data Protection Regulation (GDPR) in Europe, are meticulously designed to protect human data and the rights of human research subjects.[56] They have little to say about the ethical status of non-human genomic data.

This new research paradigm forces us to confront complex new questions. Who "owns" the genome of a species? Does a nation have a claim of sovereignty over the genomic data of its endemic wildlife? This line of inquiry connects directly to existing international agreements like the Nagoya Protocol on Access and Benefit-Sharing, which aims to ensure the fair and equitable sharing of benefits arising from the utilization of genetic resources. If a blockbuster drug for obesity is developed based on a key genetic insight from the 13-lined ground squirrel, a species native to North America, do the communities and ecosystems where that animal lives have a right to share in the profits generated from that discovery? The success of platforms like

Fauna Brain will necessitate a crucial expansion of our bioethical frameworks to include principles of environmental and interspecies justice. This will require the development of new legal and ethical structures to govern the responsible and equitable commercialization of the planet's collective biological heritage, a global conversation that is currently only in its infancy.

The Ethics of Prediction and Foreknowledge (IC Clock)

Societal Implications

The development of a simple, scalable, and validated blood test like the IC Clock, which can accurately predict an individual's rate of functional decline and mortality risk, has profound and deeply challenging societal implications. While such a tool has immense potential for good in clinical and research settings, there is also a significant risk that it could be used for discriminatory purposes. Life insurance companies, long-term care insurers, and even employers could potentially seek to use IC Clock scores to inform their decisions, leading to higher premiums, denial of coverage, or discriminatory hiring practices against individuals with a "biologically older" or faster-aging profile.[65] This could create new forms of biological discrimination that are not adequately covered by existing laws.

Psychological Burden

On a personal level, the knowledge of one's "biological age" or predicted rate of aging can create a significant psychological burden. Receiving a result that suggests one is aging faster than their peers could induce profound anxiety, fatalism, or depression, fundamentally altering an individual's relationship with their own future and their mortality.[65] While some may be motivated by such information to make positive lifestyle changes, others may be harmed by it, highlighting the need for careful consideration of how such information is delivered and supported by counseling and

context.

Equity and Social Determinants

A further ethical complication arises from the fact that epigenetic patterns are not determined by genetics alone. They are known to be heavily influenced by lifelong environmental exposures and socioeconomic status. Factors like poverty, chronic stress, exposure to pollution, and poor nutrition can all leave their mark on the epigenome and accelerate biological aging.[62] Therefore, an epigenetic clock like the IC Clock could inadvertently become a tool that biologically codifies and reinforces existing social inequalities. It risks "blaming the victim" by assigning a poor biological aging score to an individual whose health status is largely the result of structural disadvantages and societal inequities over which they had little control.[70] This could lead to a dangerous cycle of stigmatization and further disadvantage.

The greatest strength of the IC Clock—its direct and validated link to functional capacity—is also its greatest ethical vulnerability. This link may create a scientifically "legitimate" loophole for discrimination that is not adequately covered by existing legal protections, such as the Genetic Information Nondiscrimination Act (GINA) in the United States. GINA provides important protections against the use of genetic *information* by health insurers and employers, but its scope is limited. Crucially, it does not apply to life insurance, disability insurance, or long-term care insurance.[70]

An insurer might find it difficult to justify discrimination based on a more abstract biomarker that only predicts general mortality risk. However, the IC Clock does not just predict mortality; it predicts the future decline of specific, measurable functions like mobility and cognition.[16] A long-term care insurance company could plausibly argue that a poor IC Clock score is not merely "genetic information" but a direct, validated biomarker of a future high-cost condition (i.e., the need for long-term care). They could claim this makes it a legitimate actuarial basis for setting premiums or denying coverage altogether. Similarly, an employer for a physically or cognitively demanding job could argue that using the clock to screen out applicants with a high risk of future functional decline is a matter of workplace safety and suitability.

The clinical validity of the IC Clock thus makes it a far more potent and dangerous tool for potential misuse than previous, more abstract biomarkers of aging. Its development and eventual commercialization must be accompanied by a proactive

and vigorous push for new, stronger legislation. This legislation must explicitly prohibit the use of *any* biological aging marker, regardless of its predictive power for function, in underwriting or employment decisions. Without such robust legal firewalls, we risk creating a new and insidious molecular-level caste system, where an individual's opportunities and access to security are determined by the epigenetic signature in their blood.

Future Directions: The Next Steps in Extending Functional Life

Translational Roadmap for Neuro-CAR-T

Immediate Next Steps

The path forward for the Buck Institute's promising CAR-immune cell technology is clear, following the established trajectory of cell therapy development. The immediate and critical next step, as articulated by the researchers themselves, is to transition from the current *in vitro* validation to *in vivo* testing in a relevant animal model.[9] This will involve several key stages. First, the CAR-immune cells must be further engineered to carry a specific therapeutic "payload." This could be a gene encoding an anti-inflammatory cytokine like IL-10, a neurotrophic factor like BDNF, or an enzyme designed to help break down protein aggregates. Second, these fully engineered cells will be introduced into a transgenic mouse model of Alzheimer's disease. The primary goals of these preclinical studies will be to assess whether the cells can successfully traffic into the brain, locate and bind to their amyloid or tau targets, release their therapeutic payload, and, most importantly, produce a measurable therapeutic effect—such as reducing plaque load, decreasing neuroinflammation, and improving cognitive performance in the mice—all without causing unacceptable toxicity or adverse effects.[9]

Long-Term Vision - Programmable Medicine

The long-term vision for this technology extends far beyond a single treatment for Alzheimer's disease. If the platform can be proven safe and effective, it could be adapted to treat a wide range of neurodegenerative and autoimmune diseases that involve the immune system and the presence of extracellular protein aggregates, such as Parkinson's disease, amyotrophic lateral sclerosis (ALS), and multiple sclerosis.[9] The ultimate goal is the creation of a new class of "smart therapeutics." These would be programmable, mobile drug factories that can be modularly engineered with different targeting systems (CARs) and different therapeutic outputs (payloads) to address a wide variety of diseases.[23]

For this vision to become a clinical reality, several key technological hurdles will need to be overcome. The development of "off-the-shelf" allogeneic CAR-immune cells, derived from healthy donors rather than the patient themselves, would be a major breakthrough. This would eliminate the costly and time-consuming process of personalized manufacturing and allow the therapy to be readily available for any patient.[71] Additionally, the incorporation of robust safety features, such as inducible "kill switches" that allow doctors to eliminate the engineered cells from the body if severe side effects occur, will be critical for ensuring patient safety and gaining regulatory approval for broad clinical use.[71]

Projected Impact of Regenerative Medicine (HRX-215)

Expanding Indications

While the current Phase Ib/IIa trial for HRX-215 is strategically focused on the acute setting of preventing post-hepatectomy liver failure, the long-term potential for MKK4 inhibitors is much broader, encompassing the treatment of chronic liver diseases. The promising preclinical data that showed the compound has significant anti-fibrotic and anti-steatotic effects suggests that it could have powerful applications in treating

some of the most prevalent and challenging liver conditions.[28] These could include nonalcoholic steatohepatitis (NASH), a "silent" epidemic linked to obesity and diabetes that is becoming a leading cause of liver failure, and severe alcohol-associated hepatitis, a condition with very high short-term mortality.[12] Furthermore, the drug's ability to promote regeneration could be used to facilitate living donor liver transplantation, potentially allowing for the use of smaller liver grafts and expanding the pool of eligible donors.[12]

Shifting the Treatment Paradigm

The most significant and transformative future impact of a drug like HRX-215 would be a fundamental shift in the clinical management of liver disease, moving from a reactive to a proactive model. Currently, patients with chronic liver disease are often monitored as their condition slowly worsens over years or decades, with treatments aimed at managing symptoms and complications. If HRX-215 is proven to be safe for long-term administration, it could potentially be prescribed to patients in the early to middle stages of chronic liver disease. The goal would be to use its pro-regenerative and anti-fibrotic properties to halt or even reverse the progression towards cirrhosis and end-stage liver failure.[13]

This would be a true paradigm shift. Instead of waiting for the organ to fail and then resorting to the drastic and limited option of transplantation, clinicians could intervene early to maintain and restore the liver's own functional health. Such an approach would fundamentally alter the natural history of these devastating conditions, improve the quality of life for millions of patients, and dramatically reduce the immense burden that end-stage liver disease places on global healthcare systems and the scarce supply of donor organs.[27]

The Convergence of AI, Biomarkers, and Wearables: A Closed-Loop System for Healthspan

The disparate scientific and technological advances detailed in this report—from cellular engineering and regenerative medicine to AI platforms and novel biomarkers—are not isolated events progressing on parallel tracks. They are, in fact,

the essential component parts of a future, integrated system for personalized longevity medicine. When viewed together, they provide the first clear, tangible blueprint for how this revolutionary future will be constructed. This system will likely operate as a continuous, closed feedback loop, creating a new paradigm for proactive health management.

The process would begin with **Identification**. An individual's journey into personalized healthspan optimization will start with deep biological profiling. Artificial intelligence platforms, like the Fauna Brain system announced this week, will analyze an individual's personal multi-omic data—their genomics, proteomics, metabolomics, and epigenomics. This personal data will be compared against vast databases of human and comparative biology to identify that person's unique genetic risks and, more importantly, to uncover novel, personalized therapeutic targets that can be modulated to enhance their resilience and healthspan.[15]

The next step would be **Intervention**. Based on this deep AI-driven analysis, highly targeted and personalized interventions will be prescribed. These interventions will be the future iterations of the technologies we are seeing emerge today. It might be a bespoke CAR-Treg therapy, engineered to target a specific inflammatory pathway that the AI identified as a key driver of that individual's neuro-inflammation. Or it could be a next-generation MKK4 inhibitor, prescribed to boost the regenerative capacity of an organ that the analysis identified as being under stress.

This would be followed by continuous **Measurement**. The individual's response to the prescribed intervention will be monitored in real time and with unprecedented detail. A suite of specialized wearable devices, like the AI-enabled joint sensor, will track real-time functional data on mobility, sleep quality, metabolic response, and cardiovascular metrics.[47] In parallel, periodic and non-invasive blood tests using advanced biomarkers, like the IC Clock, will provide a deep, molecular-level readout of how the intervention is affecting the person's rate of biological aging and their overall functional capacity.[16]

Finally, the cycle closes with **Refinement**. The massive, continuous data streams generated by these advanced monitoring tools will be fed back into the individual's personal AI model. The AI will analyze their response to the therapy, compare it to predicted outcomes, and refine the therapeutic regimen in real time. It could recommend adjusting the dosage or timing of a drug, suggest specific changes to diet or exercise, or even determine that it is time to switch to a different therapeutic strategy altogether, all with the goal of continuously optimizing that individual's

healthspan trajectory.

This Identify -> Intervene -> Measure -> Refine loop represents the ultimate endgame of precision longevity medicine. It is a system that moves healthcare from its current state—a reactive, episodic, and population-based model—to one that is proactive, continuous, personalized, and perpetually adaptive. The remarkable advances announced in just the past seven days, though seemingly unconnected, provide the foundational elements and the strategic blueprint for this transformative future.

Works cited

1. Healthspan vs. Life Span: How to Support Healthy Longevity - Dr. Axe, accessed July 9, 2025, https://draxe.com/health/healthspan/
2. Longevity Supplements - - Life Extension, accessed July 9, 2025, https://www.lifeextension.com/wellness/supplements/best-longevity-supplements
3. Healthy Longevity - The Nutrition Source, accessed July 9, 2025, https://nutritionsource.hsph.harvard.edu/healthy-longevity/
4. Physiological geroscience: targeting function to increase healthspan and achieve optimal longevity - PMC - PubMed Central, accessed July 9, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC4933122/
5. Scientists Share 8 Recent Trends in Longevity Research - Unlocking Insights - InsideTracker, accessed July 9, 2025, https://www.insidetracker.com/a/articles/scientists-share-recent-trends-in-longevity-research
6. Healthspan vs. lifespan: two ways to measure longevity - Timeline, accessed July 9, 2025, https://www.timeline.com/blog/healthspan-vs-lifespan-two-different-ways-to-measure-longevity
7. (PDF) New horizons in life extension, healthspan extension and exceptional longevity - ResearchGate, accessed July 9, 2025, https://www.researchgate.net/publication/362535732_New_horizons_in_life_extension_healthspan_extension_and_exceptional_longevity
8. Maximizing Longevity and Healthspan: Multiple Approaches All Converging on Autophagy, accessed July 9, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC6742954/
9. The same technology that enables targeted immunotherapy for cancer could be used to tackle Alzheimer's - Buck Institute, accessed July 9, 2025, https://www.buckinstitute.org/news/the-same-technology-that-enables-targeted-immunotherapy-for-cancer-could-be-used-to-tackle-alzheimers/
10. Engineered CAR immune cells show promise in Alzheimer's - Longevity.Technology, accessed July 9, 2025, https://longevity.technology/news/engineered-car-immune-cells-show-promise-in-alzheimers/

11. Chimeric antigen receptors discriminate between tau and distinct amyloid-beta species, accessed July 9, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC12125761/
12. HepaRegeniX Doses First Patient in Phase Ib Trial with Small Molecule Inhibitor HRX-215 to Promote Liver Regeneration - BioSpace, accessed July 9, 2025, https://www.biospace.com/press-releases/heparegenix-doses-first-patient-in-phase-ib-trial-with-small-molecule-inhibitor-hrx-215-to-promote-liver-regeneration
13. HepaRegeniX starts dosing subjects in trial of HRX-215 in liver resection patients, accessed July 9, 2025, https://www.clinicaltrialsarena.com/news/heparegenix-subject-dosing/
14. HepaRegeniX Doses First Patient in Phase Ib Trial of HRX-215 for Liver Regeneration After Colorectal Cancer Surgery - BioPharma BoardRoom, accessed July 9, 2025, https://biopharmaboardroom.com/news/13/3427/heparegenix-doses-first-patient-in-phase-ib-trial-of-hrx-215-for-liver-regeneration-after-colorectal-cancer-surgery.html
15. Fauna Bio Unveils Fauna Brain™ AI Platform to Speed Up Nature-Inspired Drug Discovery, accessed July 9, 2025, https://synapse.patsnap.com/article/fauna-bio-unveils-fauna-brainE284A2-ai-platform-to-speed-up-nature-inspired-drug-discovery
16. A New Blood-Based Epigenetic Clock for Aging Focuses on Intrinsic Capacity, accessed July 9, 2025, https://www.buckinstitute.org/news/a-new-blood-based-epigenetic-clock-for-aging-focuses-on-intrinsic-capacity/
17. HepaRegeniX secures €15M Series C for HRX-215 liver regeneration trials, accessed July 9, 2025, https://synapse.patsnap.com/article/heparegenix-secures-E282AC15m-series-c-for-hrx-215-liver-regeneration-trials
18. Fauna Bio Unveils Fauna Brain™ AI Platform to Accelerate Drug Discovery Inspired by Nature's Most Resilient Species - SynBioBeta, accessed July 9, 2025, https://www.synbiobeta.com/read/fauna-bio-unveils-fauna-brain-tm-ai-platform-to-accelerate-drug-discovery-inspired-by-natures-most-resilient-species
19. A Novel Blood-Based Epigenetic Clock for Intrinsic Capacity Predicts Mortality and is Associated with Clinical, Immunological and Lifestyle Factors | bioRxiv, accessed July 9, 2025, https://www.biorxiv.org/content/10.1101/2024.08.09.607252v1
20. Chimeric Antigen Receptors Discriminate Between Tau and Distinct Amyloid-Beta Species, accessed July 9, 2025, https://www.biorxiv.org/content/10.1101/2025.02.05.636350v1
21. CAR T Cells: Engineering Immune Cells to Treat Cancer - NCI, accessed July 9, 2025, https://www.cancer.gov/about-cancer/treatment/research/car-t-cells
22. The Same Technology Used in Cancer Immunotherapy Could Help Target Alzheimer's, accessed July 9, 2025, https://www.technologynetworks.com/biopharma/news/the-same-technology-us

ed-in-cancer-immunotherapy-could-help-target-alzheimers-400982
23. novel car t-cell therapy for targeted treatment of neurodegenerative and autoimmune diseases technolog - Buck Institute, accessed July 9, 2025, https://www.buckinstitute.org/wp-content/uploads/2023/10/NCD-BI501-Andersen-Walton-2.pdf
24. Spontaneous and Induced B cell and T cell responses in Alzheimer's Disease - NIH RePORTER, accessed July 9, 2025, https://reporter.nih.gov/project-details/11080370
25. Ethical considerations for the use of anti-amyloid immunotherapy in patients with early Alzheimer's disease, accessed July 9, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC11095464/
26. HepaRegeniX Doses First Patient in Phase Ib Trial with Small Molecule Inhibitor HRX-215 to Promote Liver Regeneration | Morningstar, accessed July 9, 2025, https://www.morningstar.com/news/globe-newswire/1001101291/heparegenix-doses-first-patient-in-phase-ib-trial-with-small-molecule-inhibitor-hrx-215-to-promote-liver-regeneration
27. MKK4 Inhibitors—Recent Development Status and Therapeutic Potential - PubMed Central, accessed July 9, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC10144091/
28. Boosting liver regeneration: kinase inhibitor as a new tool to prevent liver failure - PMC, accessed July 9, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC11219813/
29. First-in-class MKK4 inhibitors enhance liver regeneration and prevent liver failure, accessed July 9, 2025, https://www.researchgate.net/publication/378992429_First-in-class_MKK4_inhibitors_enhance_liver_regeneration_and_prevent_liver_failure
30. HepaRegeniX | The Pharmaletter, accessed July 9, 2025, https://www.thepharmaletter.com/heparegenix
31. HepaRegeniX Initiates Phase Ib Trial of HRX-215, Aiming to Boost Liver Regeneration, accessed July 9, 2025, https://patientworthy.com/2025/06/14/heparegenix-initiates-phase-ib-trial-of-hrx-215-aiming-to-boost-liver-regeneration/
32. Cirrhosis - Symptoms and causes - Mayo Clinic, accessed July 9, 2025, https://www.mayoclinic.org/diseases-conditions/cirrhosis/symptoms-causes/syc-20351487
33. Alcohol-related liver disease - NHS, accessed July 9, 2025, https://www.nhs.uk/conditions/alcohol-related-liver-disease-arld/
34. Stem Cell-Based Therapies for Liver Diseases: State of the Art and New Perspectives - PMC, accessed July 9, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC2963137/
35. CAR-T Cell Therapy for Brain Tumors | City of Hope cancer center, accessed July 9, 2025, https://www.cityofhope.org/research/car-t-cell-therapy/car-t-cell-therapy-for-brain-tumors
36. Cellular & Gene Therapy Guidances - FDA, accessed July 9, 2025, https://www.fda.gov/vaccines-blood-biologics/biologics-guidances/cellular-gene

-therapy-guidances
37. Unlocking the promise of CAR-T - Harvard Gazette, accessed July 9, 2025, https://news.harvard.edu/gazette/story/2025/06/unlocking-the-promise-of-car-t/
38. Fauna Bio Launches Fauna Brain™ AI Platform to Accelerate Drug Discovery Inspired by Nature's Most Resilient Species - Business Wire, accessed July 9, 2025, https://www.businesswire.com/news/home/20250616249385/en/Fauna-Bio-Launches-Fauna-Brain-AI-Platform-to-Accelerate-Drug-Discovery-Inspired-by-Natures-Most-Resilient-Species
39. AI platform detects new drug targets in minutes, accessed July 9, 2025, https://www.drugtargetreview.com/news/166597/ai-platform-detects-new-drug-targets-in-minutes/
40. Fauna Bio launches AI-powered target discovery platform - Longevity.Technology, accessed July 9, 2025, https://longevity.technology/news/fauna-bio-launches-ai-powered-target-discovery-platform/
41. Fauna Bio, accessed July 9, 2025, https://www.faunabio.com/
42. Fauna pulls back curtain on agentic AI 'brain' proving its mettle in Lilly collab, accessed July 9, 2025, https://firstwordpharma.com/story/5973002
43. Fauna Bio Launches AI Platform to Accelerate Drug Discovery Inspired by Nature's Most Resilient Species - AI Insider, accessed July 9, 2025, https://theaiinsider.tech/2025/06/16/fauna-bio-launches-ai-platform-to-accelerate-drug-discovery-inspired-by-natures-most-resilient-species/
44. A blood-based epigenetic clock for intrinsic capacity predicts mortality and is associated with clinical, immunological and lifestyle factors - PubMed, accessed July 9, 2025, https://pubmed.ncbi.nlm.nih.gov/40467932/
45. Researchers Develop IC Clock to Measure Biological Aging Using Epigenetic Markers, accessed July 9, 2025, https://www.geneonline.com/researchers-develop-ic-clock-to-measure-biological-aging-using-epigenetic-markers/
46. Longevity: Could a simple blood test tell all about your aging? - Medical News Today, accessed July 9, 2025, https://www.medicalnewstoday.com/articles/a-simple-blood-test-could-indicate-how-long-you-might-live
47. Tomorrow's Cure: Keeping tabs on health with wearable tech - Mayo Clinic News Network, accessed July 9, 2025, https://newsnetwork.mayoclinic.org/discussion/tomorrows-cure-keeping-tabs-on-health-with-wearable-tech/
48. AI-enabled piezoelectric wearable device offers accurate and low-cost joint health tracking, accessed July 9, 2025, https://www.news-medical.net/news/20250707/AI-enabled-piezoelectric-wearable-device-offers-accurate-and-low-cost-joint-health-tracking.aspx
49. The Best Longevity Tech of 2025 | Super Age, accessed July 9, 2025, https://superage.com/the-best-longevity-tech-of-2025/
50. The Ethics of CAR-T Cell Therapy - Number Analytics, accessed July 9, 2025,

https://www.numberanalytics.com/blog/ethics-of-car-t-cell-therapy
51. Safety and efficacy of CAR-T cell therapy in patients with autoimmune diseases: a systematic review - PubMed, accessed July 9, 2025, https://pubmed.ncbi.nlm.nih.gov/39754644/
52. Considerations for the Development of Chimeric Antigen Receptor (CAR) T Cell Products Guidance for Industry - FDA, accessed July 9, 2025, https://www.fda.gov/media/156896/download
53. (PDF) Ethical Issues in the Treatment of Late-Stage Alzheimer's Disease - ResearchGate, accessed July 9, 2025, https://www.researchgate.net/publication/329160059_Ethical_Issues_in_the_Treatment_of_Late-Stage_Alzheimer's_Disease
54. Barriers to Accessibility for CAR-T - CGTLive®, accessed July 9, 2025, https://www.cgtlive.com/view/barriers-accessibility-car-t
55. maplespub.com, accessed July 9, 2025, https://maplespub.com/article/artificial-intelligence-in-the-genomics-era-a-blessing-or-a-curse#:~:text=This%20can%20be%20particularly%20problematic,about%20individuals%20and%20the%20families.
56. Privacy Challenges and Research Opportunities for Genomic Data Sharing - PMC, accessed July 9, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC7761157/
57. AI and Genomic Data Security: Balancing Innovation and Privacy in Precision Medicine, accessed July 9, 2025, https://www.researchgate.net/publication/384285907_AI_and_Genomic_Data_Security_Balancing_Innovation_and_Privacy_in_Precision_Medicine
58. Ethical Challenges of Artificial Intelligence in Medicine - PMC, accessed July 9, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC11670736/
59. evolving privacy and security concerns for genomic data analysis and sharing as observed from the iDASH competition - Oxford Academic, accessed July 9, 2025, https://academic.oup.com/jamia/article/29/12/2182/6717759
60. Ethical Considerations in Ai-Driven Drug Discovery. ⟶ Scenario - Prism ⟶ Sustainability Directory, accessed July 9, 2025, https://prism.sustainability-directory.com/scenario/ethical-considerations-in-ai-driven-drug-discovery/
61. Ethical Challenges in AI-Driven Drug Development - International Journal of Multidisciplinary Research and Growth Evaluation www.allmultidisc, accessed July 9, 2025, https://www.multidisciplinaryfrontiers.com/uploads/archives/20250219183353_51.pdf
62. Epigenetic clocks and research implications of the lack of data on whom they have been developed: a review of reported and missing sociodemographic characteristics - Oxford Academic, accessed July 9, 2025, https://academic.oup.com/eep/article/9/1/dvad005/7224619
63. AI And Pharmaceutical Development WHO Calls For Ethical Framework Good Governance, accessed July 9, 2025, https://www.drugdiscoveryonline.com/doc/ai-and-pharmaceutical-development-who-calls-for-ethical-framework-good-governance-0001

64. Comparative genomics of thermosynechococcaceae and thermostichaceae: insights into codon usage bias - Frontiers Publishing Partnerships, accessed July 9, 2025, https://www.frontierspartnerships.org/journals/acta-biochimica-polonica/articles/10.3389/abp.2024.13825/full
65. The Ethics of Epigenetics: A Deep Dive - Number Analytics, accessed July 9, 2025, https://www.numberanalytics.com/blog/ethics-epigenetics-deep-dive
66. Potential (mis)use of epigenetic age estimators by private companies and public agencies: human rights law should provide ethical guidance - Oxford Academic, accessed July 9, 2025, https://academic.oup.com/eep/article/5/3/dvz018/5571210
67. Epigenetic biomarkers of ageing are predictive of mortality risk in a longitudinal clinical cohort of individuals diagnosed with oropharyngeal cancer - PubMed Central, accessed July 9, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC8725548/
68. Ethical and social implications of approaching death prediction in humans - when the biology of ageing meets existential issues, accessed July 9, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC7385957/
69. [Ethical and social consequences of biomarkers that predict impending death in humans], accessed July 9, 2025, https://pubmed.ncbi.nlm.nih.gov/33296638/
70. (PDF) Ethical Implications of Epigenetics Research - ResearchGate, accessed July 9, 2025, https://www.researchgate.net/publication/24189327_Ethical_Implications_of_Epigenetics_Research
71. NYU researchers developing engineered immune cells to target Alzheimer's disease, accessed July 9, 2025, https://engineering.nyu.edu/news/nyu-researchers-developing-engineered-immune-cells-target-alzheimers-disease
72. AI Will Double the Human Lifespan: Here's How - Data Society, accessed July 9, 2025, https://datasociety.com/ai-will-double-the-human-lifespan-heres-how/
73. AI and Longevity: Can Artificial Intelligence Help Humans Live Longer?, accessed July 9, 2025, https://trendsresearch.org/insight/ai-and-longevity-can-artificial-intelligence-help-humans-live-longer/